Skip to content

Decoy Therapeutics Inc.: 10-Q filed 2020-11-12

What Decoy Therapeutics Inc. reported in its quarterly report filed 2020-11-12 (fiscal Q3 2020): 30 published measures, 84 facts as tagged in accession 0001615219-20-000113.

This filing

Form
10-Q (quarterly report)
Filed
2020-11-12
Fiscal period
fiscal Q3 2020
Accession
0001615219-20-000113 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Decoy Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-3023,063,211USD
At 2019-12-3113,894,398USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-302,457,245USD
At 2019-12-313,313,544USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-3020,605,966USD
At 2020-06-3016,854,974USD
At 2020-03-3118,002,613USD
At 2019-12-3110,580,854USD
At 2019-09-309,737,033USD
At 2019-06-30732,913USD
At 2019-03-311,730,282USD
At 2018-12-31-1,271,114USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-309,557,813USD
At 2019-12-313,738,900USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,716,632USD92
2020-01-01 to 2020-09-30-5,584,706USD274
2020-04-01 to 2020-06-30-1,784,258USD91
2020-01-01 to 2020-03-31-2,083,816USD91
2019-07-01 to 2019-09-30-2,627,721USD92
2019-01-01 to 2019-09-30-5,053,442USD273
2019-04-01 to 2019-06-30-903,645USD91
2019-01-01 to 2019-03-31-1,522,076USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-8,937,879USD274
2019-01-01 to 2019-09-30-8,943,538USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2020-07-01 to 2020-09-301,378,239USD92
2020-01-01 to 2020-09-303,754,379USD274
2019-07-01 to 2019-09-30874,949USD92
2019-01-01 to 2019-09-302,426,362USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-3014,756,792USD274
2019-01-01 to 2019-09-301,203,525USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-305,607,908USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-17,661,406USD
At 2019-12-31-12,076,700USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-3015,635USD
At 2019-12-3125,016USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-09-30149,660USD274
2019-01-01 to 2019-09-30579,721USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,758,505USD92
2020-01-01 to 2020-09-30-6,029,017USD274
2019-07-01 to 2019-09-30-3,760,165USD92
2019-01-01 to 2019-09-30-6,205,051USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-3013,919,158USD
At 2019-12-314,694,799USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-09-301,195,063USD
At 2019-12-311,790,966USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2020-09-308,865,909USD
At 2019-12-318,865,909USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-303,136,744USD92
2020-01-01 to 2020-09-309,783,396USD274
2019-07-01 to 2019-09-304,635,114USD92
2019-01-01 to 2019-09-308,631,413USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-301,803,682USD92
2020-01-01 to 2020-09-304,890,375USD274
2019-07-01 to 2019-09-301,140,909USD92
2019-01-01 to 2019-09-302,680,982USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-3019,818,912shares
At 2019-12-314,511,174shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-09-309,557,813USD
At 2019-12-313,738,900USD
At 2019-09-303,999,676USD
At 2018-12-316,131,781USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-3038,265,391USD
At 2019-12-3122,657,103USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-09-30262,509USD
At 2019-12-31308,674USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-09-301,148,667USD
At 2019-12-31955,899USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2020-09-300USD
At 2019-12-31541,701USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-301,333,062USD92
2020-01-01 to 2020-09-304,893,021USD274
2019-07-01 to 2019-09-303,494,205USD92
2019-01-01 to 2019-09-305,950,431USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-01-01 to 2020-09-3012,699USD274
2019-01-01 to 2019-09-30123,174USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-09-306,615USD274
2019-01-01 to 2019-09-306,867USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-30-690USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-30-1,169USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-607,904USD274
2019-01-01 to 2019-09-30-593,351USD273

Inspect the source

Entity
Decoy Therapeutics Inc. / CIK 0001615219
Captured
SEC response SHA-256
3dae29679ef228e32bff301a79640d7e283fcc5b87c08a4882faedfce1c66e98

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001615219.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))